Impact of ERCC2 Gene Polymorphisms on OSCC Susceptibility and Clinical Characteristics

Abstract

Background DNA repair systems play an important role in maintaining the integrity of the human genome. Deficiency in the repair capacity due to either mutations or inherited polymorphisms in DNA repair genes may contribute to variations in the DNA repair capacity and subsequently susceptibility to cancer.
Objectives This study aimed to investigate the association between Excision repair cross-complementation groups 2 (ERCC2) single nucleotide polymorphisms (SNPs rs1799793 and rs13181) and the response to platinum-based chemotherapy among patients with oral squamous cell carcinoma (OSCC).
Methodology Polymerase chain reaction‐based restriction fragment length polymorphism analysis was used to determine the polymorphism from a total of 150 OSCC patients and 150 normal tissues of same patients were collected as controls for this study.
Results ERCC2 GA (Asp312Asn) AC (Lys751Gln) genotypes were significantly associated (p = 0.0001 and p = 0.0004, respectively) with OSCC patients, when compared with the controls. These findings suggest that potentially functional SNPs in ERCC2 may contribute to OSCC risk. This study highlights the genetic variant that might play a role in mediating susceptibility to OSCC in this population. An understanding of DNA repair gene polymorphisms might not only enable risk assessment, but also response to therapy, which target the DNA repair pathway.

Keywords

oral cancer / ERCC2 / DNA repair / platinum-based chemotherapy

References

[1] Huang X, Gao Y, He J, et al. The association between RFC1 G80A polymorphism and cancer susceptibility: evidence from 33 studies. J Cancer 2016; 7(02): 144-152

[2] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(05): 646-674

[3] Biason P, Hattinger CM, Innocenti F, et al. Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy. Pharmacogenomics J 2012; 12(06): 476-483

[4] Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 2007; 39(7-8): 1318-1328

[5] Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 2007; 4(02): 59-71

[6] Weber CA, Salazar EP, Stewart SA, Thompson LH. ERCC2: cDNA cloning and molecular characterization of a human nucleotide excision repair gene with high homology to yeast RAD3. EMBO J 1990; 9(05): 1437-1447

[7] Chen JZ, Kadlubar FF. A new clue to glaucoma pathogenesis. Am J Med 2003; 114(08): 697-698

[8] Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrini AM, Egly JM. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet 1998; 20(02): 184-188

[9] Mitra AK, Singh N, Garg VK, Chaturvedi R, Sharma M, Rath SK. Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to squamous cell carcinomas of the head and neck (SCCHN) and breast cancer in the north Indian population. J Exp Clin Cancer Res 2009; 28: 104

[10] Sung P, Bailly V, Weber C, Thompson LH, Prakash L, Prakash S. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993; 365(6449): 852-855

[11] Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1(01): 22-33

[12] Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 2002; 17(06): 463-469

[13] Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000; 21(04): 551-555

[14] Hou SM, Fält S, Angelini S, et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002; 23(04): 599-603

[15] Au WW, Salama SA, Sierra-Torres CH. Functional characterization of polymorphisms in DNA repair genes using cytogenetic challenge assays. Environ Health Perspect 2003; 111(15): 1843-1850

[16] Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61(04): 1354-1357

[17] Bau DT, Wu HC, Chiu CF, et al. Association of XPD polymorphisms with prostate cancer in Taiwanese patients. Anticancer Res 2007; 27(4C): 2893-2896

[18] Li M, Zhao Y, Zhao E, Wang K, Lu W, Yuan L. Predictive value of two polymorphisms of ERCC2, rs13181 and rs1799793, in clinical outcomes of chemotherapy in gastric cancer patients: a meta-analysis. Dis Markers 2018; 2018: 3947626

[19] Vella N, Aiello M, Russo AE, et al. ‘Genetic profiling' and ovarian cancer therapy (review). Mol Med Rep 2011; 4(05): 771-777

[20] Smolarz B, Makowska M, Samulak D, et al. Single nucleotide polymorphisms (SNPs) of ERCC2, hOGG1, and XRCC1 DNA repair genes and the risk of triple-negative breast cancer in Polish women. Tumour Biol 2014; 35(04): 3495-3502

RIGHTS & PERMISSIONS

2020 Global Medical Genetics